ArticleBiomolecules2022
Plasma Polyamine Biomarker Panels: Agmatine in Support of Prostate Cancer Diagnosis.
Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Assessing the Predictive Power of the Hemoglobin/Red Cell Distribution Width Ratio in Cancer: A Systematic Review and Future Directions.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Ferroptosis and Senescence: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Evaluation of agmatine's anti-cancer efficacy in Caco-2 colorectal adenocarcinoma cells.Medical oncology (Northwood, London, England) · 2026Article
- Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification.Clinical and experimental medicine · 2025Article
- Diagnostic Stratification of Prostate Cancer Through Blood-Based Biochemical and Inflammatory Markers.Diagnostics (Basel, Switzerland) · 2025Article
- Associations between plasma and urinary heavy metal concentrations and the risk of prostate cancer.Scientific reports · 2025Article
- Role of Blood Cell Indexes in Progresses to ESRD.Indian journal of clinical biochemistry : IJCB · 2025Article
- Modulation of adipose-derived stem cell behavior by prostate pathology-associated plasma: insights from in vitro exposure.Scientific reports · 2024Article
- Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges.Medicina (Kaunas, Lithuania) · 2023Review
- Decoding the Microbiome's Influence on Rheumatoid Arthritis.Microorganisms · 2023Review
- Review
- Quantitative Metabolomics to Explore the Role of Plasma Polyamines in Colorectal Cancer.International journal of molecular sciences · 2022Article
- Role of Polyamines as Biomarkers in Lymphoma Patients: A Pilot Study.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most frequent malignant tumour among males (19%), often clinically silent and of difficult prognosis. Although several studies have highlighted the diagnostic and prognostic role of circulating biomarkers, such as PSA, their measurement does not necessarily allow the detection of the disease. Within this context, many authors suggest that the evaluation of circulating polyamines could represent a valuable tool, although several analytical problems still counteract their clinical practice. In particular, agmatine seems particularly intriguing, being a potential inhibitor of polyamines commonly derived from arginine. The aim of the present work was to evaluate the potential role of agmatine as a suitable biomarker for the identification of different classes of patients with prostate cancer (PC). For this reason, three groups of human patients-benign prostatic hyperplasia (BPH), precancerous lesion (PL), and prostate cancer (PC)-were recruited from a cohort of patients with suspected prostate cancer (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.